AR and prostate carcinoma: CAPE downregulated the expression of androgen receptor (AR) and mucosa-associated lymphoid tissue 1 (MALT1) but enhanced that of p53, thus decreasing androgen-induced activation of MALT1 and prostate-specific antigen expressions in AR-positive prostate carcinoma cells.